CELEBREX Drug Patent Profile

When do Celebrex patents expire, and what generic alternatives are available?

Celebrex is a drug marketed by Upjohn and is included in one NDA.

The generic ingredient in CELEBREX is celecoxib. There are twenty-six drug master file entries for this compound. Sixty-four suppliers are listed for this compound. Additional details are available on the celecoxib profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Celebrex

A generic version of CELEBREX was approved as celecoxib by TEVA on May 30^th, 2014.

Summary for CELEBREX

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for CELEBREX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CELEBREX	Capsules	celecoxib	50 mg	020998	1	2008-03-21

US Patents and Regulatory Information for CELEBREX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-004	Dec 15, 2006	AB	RX	Yes	No
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-003	Aug 29, 2002	AB	RX	Yes	Yes
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-001	Dec 31, 1998	AB	RX	Yes	No
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-002	Dec 31, 1998	AB	RX	Yes	No

International Patents for CELEBREX

See the table below for patents covering CELEBREX around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2180233
Australia	690609
European Patent Office	0923933	Pyrazolyl-benzènesulfonamides destinés à l'utilisation pour le traitement de l'inflammation (Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation)
Denmark	0922697
Hong Kong	1013649

Supplementary Protection Certificates for CELEBREX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0731795	4/2009	Austria		PRODUCT NAME: MAVACOXIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/2/08/084/001-005 20080909
0731795	09C0007	France		PRODUCT NAME: MAVACOXIB; REGISTRATION NO/DATE: EU/2/08/084/001 20080909
2488169	C202330042	Spain		PRODUCT NAME: COCRISTAL DE TRAMADOL, OPCIONALMENTE EN FORMA DE UNA SAL FISIOLOGICAMENTE ACEPTABLE, Y CELECOXIB; NATIONAL AUTHORISATION NUMBER: 89051; DATE OF AUTHORISATION: 20230925; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 89051; DATE OF FIRST AUTHORISATION IN EEA: 20230925
0731795	SZ 4/2009	Austria		PRODUCT NAME: MAVACOXIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES
0731795	0090013-4	Sweden

CELEBREX (Celecoxib) Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Celecoxib, marketed as CELEBREX by Pfizer, is a nonsteroidal anti-inflammatory drug (NSAID) primarily used to treat osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and acute pain. Its selectivity for COX-2 enzymes distinguishes it from traditional NSAIDs, influencing its safety profile and market positioning. This analysis explores the current investment landscape, market dynamics, and financial trajectory for CELEBREX, emphasizing patent status, competition, regulatory factors, and commercial outlook from 2023 onward.

---

1. Patent and Regulatory Landscape

1.1 Patent Expiry and Exclusivity

Patent Type	Original Patent Expiry	Secondary/Patent Extensions	Current Patent Status	Impact on Market Launches
Composition of Matter	2014	Patent extensions until 2020	Generic versions launched post-2015	Increased market competition
Method of Use	Extended to 2022	-	Some patent protections lapsed	Limited patent protection for new indications

Sources: Pfizer SEC filings, FDA Orange Book (2022)[1]

1.2 Regulatory Approvals & Labeling

• FDA Approval Date: July 1998
• Indications: OA, RA, ankylosing spondylitis, acute pain
• Black Box Warning: Cardiovascular risk associated with NSAIDs, including COX-2 inhibitors
• Generic Approval: Multiple generics approved since 2015, affecting market pricing and margins

---

2. Market Dynamics

2.1 Global Market Size & Growth Trajectory

Year	Market Size (USD billion)	CAGR (2021-2026)	Key Drivers
2021	2.5	5.1%	Rising prevalence of arthritis, aging populations, shift toward NSAIDs
2022	2.65	5.2%	Increased adoption of COX-2 inhibitors
2023	2.8	5.3%	Greater awareness, expanding markets in Asia-Pacific

Sources: GlobalData, 2022[2]

2.2 Competitive Landscape

Competitors	Drug Name	Mechanism	Market Share (2022)	Key Differentiator
Traditional NSAIDs	Diclofenac, Ibuprofen	Non-selective NSAIDs	~40% combined	Cost-effective, well-established
Other COX-2 inhibitors	Etoricoxib, Meloxicam	COX-2 selective	~35% combined	Similar efficacy, some marketed for specific indications
Emerging Biologics	Tocilizumab, Upadacitinib	Disease-modifying	~10%	Targeted therapies for RA

Sources: IQVIA, 2022[3]

2.3 Pricing and Reimbursement Trends

• Brand vs. Generic Pricing: Original branded CELEBREX historically maintained a premium; generics drove significant price erosion.
• Reimbursement Policies: Vary across markets, with payers scrutinizing NSAIDs' cardiovascular risks.
• Impact of Black Box Warnings: May hinder prescribing rates, influencing revenue trajectory.

---

3. Financial Trajectory and Investment Outlook

3.1 Revenue Trends and Projections

Year	Estimated Revenue (USD million)	Notes
2022	150	Post-patent expiry, impact of generics
2023	100-120	Continued generic competition, potential off-label use
2024-2026	80-100	Market saturation, conservative growth assumptions

Assumptions based on Pfizer disclosures, market reports[1,2]

3.2 Impact of Generic Competition

• Market Share Erosion: Predominantly affecting branded CELEBREX, with generics capturing >85% since 2015.
• Pricing: Average selling price (ASP) declined by ~60% since patent expiration.
• Strategies: Pfizer and competitors have explored biosimilars, combination therapies, and new indications to recapture market share.

3.3 Future Revenue Drivers

Driver	Effect	Expected Timeline
New Indications	Potential for expanded use	2024-2026
Biosimilar Entry	Increased competition	Post-2025
Shift Toward Personalized Medicine	Niche markets, high-margin segments	2025+
Digital Health Integration	Monitoring compliance, telemedicine	2023 onward

---

4. Investment Risks and Opportunities

4.1 Risks

Risk Factor	Description	Mitigation Strategies
Patent Cliff	Loss of exclusivity	Diversification into new indications
Cardiovascular Risks	Litigation, regulatory scrutiny	Precise patient targeting, education
Market Saturation	Price erosion	Optimization of manufacturing costs
Competition from Biologics	Displacement of NSAIDs	Focus on niche indications

4.2 Opportunities

Opportunity	Strategy	Expected Benefit
Label Expansion	New indications (e.g., chronic pain)	Revenue growth
Geographic Expansion	Emerging markets	Volume growth
Digital & Data Analytics	Enhanced patient engagement	Differentiation

---

5. Comparison with Similar Drugs

Aspect	CELEBREX (Celecoxib)	Etoricoxib	Meloxicam	Diclofenac
Mechanism	COX-2 selective	COX-2 selective	Non-selective	Non-selective
Patent Status	Lapsed 2020s	Pending generic entrance	Patent expired	Generic
CV Risk	Elevated	Similar	Lower	Similar
Pricing	Moderate to high (brand)	Similar	Low	Low
Approved Uses	OA, RA, ankylosing spondylitis	Similar	Similar	OA, RA

---

6. Strategic Recommendations for Investors

• Focus on Patent-Lite Dynamics: Recognize revenue decline post-patent expiration; consider licensing or diversification.
• Monitor Regulatory Developments: Watch for label updates, especially concerning safety warnings affecting sales.
• Evaluate Specialty Segments: Potential niche markets for COX-2 inhibitors with better safety profiles.
• Assess Geographic Markets: Rapid growth in Asian markets presents diversification opportunities.
• Identify Pipeline and Biosimilar Risks: Be aware of imminent biosimilar entries impacting pricing strategies.

---

7. Deep Dive: Key Market and Financial Metrics

Metric	2022	2023 (Forecast)	2024-2026 (Forecast)
Global Market Size (USD billion)	2.5	2.65	2.8–3.0
Brand Market Share	>15%	<10%	<5%
Generic Market Share	~85%	~95%	>95%
Average Selling Price (USD) per prescription	USD 150	USD 100	USD 70–80
Pfizer Revenue (USD million)	USD 150	USD 100–120	USD 80–100

---

Conclusion

CELEBREX's investment outlook is constrained by patent expirations, generic competition, and safety considerations. While current revenues reflect significant erosion post-2015, opportunities exist through emerging indications, geographic expansion, and niche segmentation. Forward-looking strategies should prioritize diversification, safety profile management, and innovation in delivery and application to sustain long-term value.

---

Key Takeaways

• Patent expiry led to sharp revenue decline; generic penetration exceeds 85% since 2015.
• Market growth remains steady but faces pressure from cheaper generics and biosimilars.
• Safety concerns related to cardiovascular risks continue to influence prescribing and regulatory environment.
• Opportunities exist in niche markets, geographic expansion, and digital health integration.
• Strategic positioning requires balancing patent cliffs, safety profiles, and emerging competitive threats.

---

FAQs

1. What is the current patent status of CELEBREX?

The original composition of matter patent expired in 2014, with secondary patents extending protections for specific uses until around 2022, after which generic versions dominate the market.

2. How has generic competition impacted CELEBREX's revenue?

Generic entry since 2015 has resulted in over 85% market share captured by generics, leading to a revenue decline from approximately USD 150 million in 2022 to an estimated USD 80–100 million by 2024.

3. Are there ongoing efforts to expand CELEBREX’s labeled indications?

Yes, exploration of new indications, such as chronic pain management or specific inflammatory conditions, remains a potential growth avenue pending regulatory approval.

4. What are the main safety concerns affecting CELEBREX?

Cardiovascular risks, including increased likelihood of thrombotic events, are the primary safety warnings influencing prescriber behavior and regulatory reviews.

5. How does CELEBREX compare to other COX-2 inhibitors?

Celecoxib is among the most established COX-2 inhibitors with a well-documented efficacy profile and a black box warning for cardiovascular risk, similar to etoricoxib. Market shares are divided, with newer biologics capturing portions of the RA patient segment.

---

References

[1] Pfizer Inc. (2022). FDA Orange Book.
[2] GlobalData. (2022). Global NSAID Market Report.
[3] IQVIA. (2022). Pharmaceutical Market Insights.

---

Note: All financial estimates are projections based on available market data and are subject to change due to competitive, regulatory, and market forces.